Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
出版年份 2014 全文链接
标题
Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
作者
关键词
-
出版物
Science Signaling
Volume 7, Issue 318, Pages ra29-ra29
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2014-03-26
DOI
10.1126/scisignal.2005125
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
- (2013) Y. Yan et al. CLINICAL CANCER RESEARCH
- ErbB3 downregulation enhances luminal breast tumor response to antiestrogens
- (2013) Meghan M. Morrison et al. JOURNAL OF CLINICAL INVESTIGATION
- The Gray Institute ‘open’ high-content, fluorescence lifetime microscopes
- (2013) P.R. BARBER et al. JOURNAL OF MICROSCOPY
- Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology
- (2013) N. T. Viola-Villegas et al. JOURNAL OF NUCLEAR MEDICINE
- Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
- (2013) M. Yu et al. SCIENCE
- Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
- (2013) D. C. Kirouac et al. Science Signaling
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
- (2012) F. Andre et al. ANNALS OF ONCOLOGY
- Neoadjuvant treatments for triple-negative breast cancer (TNBC)
- (2012) G. von Minckwitz et al. ANNALS OF ONCOLOGY
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
- (2012) C. Garcia-Garcia et al. CLINICAL CANCER RESEARCH
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
- (2011) Rebekka Krumbach et al. EUROPEAN JOURNAL OF CANCER
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Directed Therapy of Subtypes of Triple-Negative Breast Cancer
- (2011) L. A. Carey ONCOLOGIST
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients
- (2011) Phillip Kim et al. Proteome Science
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Kinase-mediated quasi-dimers of EGFR
- (2010) Erez M. Bublil et al. FASEB JOURNAL
- Triple-negative breast cancer: disease entity or title of convenience?
- (2010) Lisa Carey et al. Nature Reviews Clinical Oncology
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isolation of circulating tumor cells using a microvortex-generating herringbone-chip
- (2010) S. L. Stott et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress
- (2009) Joanna R. Morris et al. NATURE
- Inhibitor hijacking of Akt activation
- (2009) Tatsuya Okuzumi et al. Nature Chemical Biology
- Standardized methods for the production of high specific-activity zirconium-89
- (2009) Jason P. Holland et al. NUCLEAR MEDICINE AND BIOLOGY
- Pattern of metastatic spread in triple-negative breast cancer
- (2008) Rebecca Dent et al. BREAST CANCER RESEARCH AND TREATMENT
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started